A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
- To evaluate the safety and tolerability of escalating doses of ERAS-601 when
administered as a monotherapy and in combination with other cancer therapies in study
participants with advanced or metastatic solid tumors.
- To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601
when administered as a monotherapy and in combination with other cancer therapies.
- To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a
monotherapy and in combination with other cancer therapies.
- To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in
combination with other cancer therapies.